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Background: In order to search for new structural modification strategies on fluoroquinolones, we have designed
and synthesized a series of fluoroquinolone derivatives by linking various hydrazine compounds to the C-3 carboxyl
group of levofloxacin and assessed their anticancer activities. Several novel levofloxacin derivatives displayed potent
cytotoxicity against the tested cancer cell lines in vitro. In the present study, we investigated the effect of
1-Cyclopropyl-6-fluoro-4-oxo-7- piperazin-1, 4-dihydro- quinoline- 3-carboxylic acid benzo [1,3]
dioxol-5- ylmethylene- hydrazide (QNT11) on the apoptosis of human hepatocarcinoma cells in vitro.
Methods: The inhibition effects of QNT11 on cell proliferation were examined by MTT assay. Cell apoptosis was
determined by TUNEL and DNA agarose gel electrophoresis method. The topoisomerase ΙΙ activity was measured
by agarose gel electrophoresis using Plasmid pBR322 DNA as the substrate. Cell cycle progression was analyzed
using flow cytometry in conjunction with ethanol fixation and propidium iodide staining. Mitochondrial membrane
potential (△ψm) was measured by high content screening image system. The caspase-9, caspase-8, caspase-3, Bcl-2,
Bax, CDK1, Cyclin B1and cytochrome c protein expressions were detected by Western blot analysis.
Results: QNT11 showed selective cytotoxicity against Hep3B, SMMC-7721, MCF-7 and HCT-8 cell lines with IC50 values
of 2.21 μM, 2.38 μM, 3.17 μM and 2.79 μM, respectively. In contrast, QNT11 had weak cytotoxicity against mouse bone
marrow mesenchymal stem cells (BMSCs) with IC50 value of 7.46 μM. Treatment of Hep3B cells with different
concentrations of QNT11 increased the percentage of the apoptosis cells significantly, and agarose gel electrophoresis
revealed the ladder DNA bands typical of apoptotic cells, with a decrease in the mitochondrial membrane potential.
Compared to the control group, QNT11 could influence the DNA topoisomerase IIactivity and inhibit the religation of
DNA strands, thus keeping the DNA in fragments. There was a significant increase of cytochrome c in the cytosol after
24 h of treatment with QNT11 and a decrease in the mitochondrial compartment. Observed changes in cell cycle
distribution by QNT11 treated might be caused by insufficient preparation for G2/M transition. In addition, QNT11
increased the protein expression of Bax, caspase-9, caspase-8, caspase-3, as well as the cleaved activated forms of
caspase-9, caspase-8 and caspase-3 significantly, whereas the expression of Bcl-2 decreased.
Conclusions: Our results showed that QNT11 as a fluoroquinolone derivative exerted potent and selectively anticancer
activity through the mechanism of eukaryotic topoisomerase II poisoning. The growth inhibition was in large part
mediated via apoptosis-associated mitochondrial dysfunction and regulation of Bcl-2 signaling pathways.
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Figure 1 Chemical structure of 1-Cyclopropyl-6-fluoro-4-oxo-7-
piperazin-1, 4-dihydro-quinoline-3-carboxylic acid benzo [1,3]
dioxol-5-ylmethylene- hydrazide (QNT11).
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Antibacterial fluoroquinolone is a very important family
of antibacterial drugs that are widely prescribed for the
treatment of infections in humans [1]. According to the
pharmacological mechanisms elucidated in numerous
reports, antibacterial fluoroquinolone corrupts the activ-
ities of prokaryotic type II topoisomerase, DNA gyrase,
and induces them to kill cells by generating high levels
of double-stranded DNA breaks. DNA gyrase modulates
the topological state of the genetic material by passing an
intact DNA helix through a transient double-stranded
break to generate a separate DNA segment [2]. Like bacter-
ial cells, eukaryotic species also require a type II topoisom-
erase, known as topoisomeraseII, for viability. Comparing
the known sequences of type II topoisomerases of bacteria
and mammals, the sequences around activated tyrosine
residues appear to have common homology [3]. The
mechanisms responsible for cell killing by antitumor
fluoroquinolones also appear to be similar to that of
quinolone antibacterial agents [4]. Although 100-fold more
sensitive to prokaryotic DNA gyrase, fluoroquinolones also
have some inhibitory effects on mammalian DNA topo-
isomerase II. In addition, their mode of action is similar to
that of anthracycline derivatives (such as doxorubicin,
amsacrine, mitoxantrone), epipodophyllotoxin derivatives
(such as etoposide), and actinomycin D (a class of po-
lypeptide antibiotics isolated from Streptomyces). For this
reason, antibacterial fluoroquinolones have been shown to
have cytotoxic activity against cancer cells [5,6], thus
representing a potentially important source of new anti-
cancer agents.
Recently, the development of antitumor agents out of
antibacterial fluoroquinolones has attracted much atten-
tion based on the mechanistic similarities and sequence
homologies of the targeting eukaryotic topoisomerases
[7]. However, many antitumor fluoroquinolones were
modified from clinical antibacterial fluoroquinolones
with regard to the nitrogen-containing ring, such as
piperazine, on the 7-position and (or) the 2-position of
fluoroquinolone scaffold [8,9]. In addition, a few modifi-
cations for the carboxylic group at the 3-position were
reported [10]. Indeed, it doesn’t seem necessary for an
antitumor fluoroquinolone to retain the carboxylic
group; fluroquinolones with a fused heterocyclic ring as
an isostere of the carboxylic group showed good anti-
cancer activity as well as excellent water solubility [11].
To search for new structural modification strategies
on antibacterial fluoroquinolones, we have designed and
synthesized a series of fluoroquinolone derivatives by
linking various hydrazine compounds to the C-3 carb-
oxyl group of ofloxacin or ciprofloxacin and assessed
their anticancer activities. Several novel levofloxacin de-
rivatives displayed potent cytotoxicity against the tested
cancer cell lines in vitro, where the IC50 values of thecompounds reached micromolar concentration [12].
The IC50 of QNT11 (1-Cyclopropyl-6-fluoro-4-oxo-7-
piperazin-1, 4-dihydro- quinoline- 3-carboxylic acid
benzo [1,3] dioxol-5-ylmethylene- hydrazide) was the
lowest among the levofloxacin derivatives. Therefore we
investigated the growth inhibitory effects and the
molecular mechanisms of QNT11 in human hepato-
carcinoma cells in vitro. We found that QNT11 showed
potent cytotoxicity against Hep3B cells with an IC50
value of 2.21 μM. We also investigated the signal path-
ways of QNT11-induced apoptosis.
Methods
Chemicals
Trimethoxy-benzaldehyde levofloxacin hydrazone (QNT11)
was synthesized at the Institute of Chemistry and Biology at
Henan University. The purity was more than 98% by HPLC
analysis. The compound was dissolved in dimethyl sulfoxide
(DMSO). Its structure is illustrated in Figure 1.
Cell culture
Human hepatocarcinoma cells (Hep3B2.1-7 and SMMC-
7721), human breast adenocarcinoma cells (MCF-7), and
human colon adenocarcinoma cells (HCT-8) from the
Institute of Cytology, Chinese Academy of Sciences
(Shanghai, China), were cultured in DMEM medium
(Gibco BRL, USA) supplemented with 10% (v/v) heat-
inactivated fetal bovine serum, 100 IU/ml penicillin and
100 μg/ml streptomycin. The cells were maintained in
5% CO2, at 37°C until reaching approximately 50%-70%
confluence and were then treated with different amounts
of chemicals as indicated. DMSO alone was used as the
vehicle control.
Isolation of BMSCs
Bone marrow from the tibias and femurs of approxi-
mately 8 week old mice was flushed with DMEM. The
marrow cells were dissociated by passage through a 25-
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1000 rpm for 5 min, re-suspended in DMEM medium
supplemented with 10% (v/v) fetal bovine serum, 100 IU/ml
penicillin and 100 μg/ml streptomycin, and plated in
100 mm culture dishes with supplemented DMEM and
maintained in 5% CO2, at 37°C for 24 h, the medium
containing the non-adherent cells was removed, and the ad-
herent cells were gently washed 2 times with PBS to reduce
the degree of hematopoietic lineage cell contamination.
The cells were cultured in DMEM for 3–4 weeks, until they
reached 50-70% confluence.
MTT assay
The cells were seeded at a density of 1 × l04 cells/well in
96-well culture plates, and 24 h later they were treated
with the indicated concentrations of QNT11 or levo-
floxacin. Control wells consisted of cells incubated with
medium only. After 12, 24, 48 and 72 h of treatment, cells
were incubated with 20 μl 3-(4,5-dimethylthiazol-2-yl)
2,5-diphenyltetrazolium bromide (MTT, Sigma, St Louis,
MO, USA) at 5 mg/ml. After 4 h at 37°C, the supernatant
was removed, and 150 μl DMSO was added. After the
blue crystals were dissolved in DMSO, the optical density
(OD) was then detected at a 570 nm wavelength using a
96-well multiscanner autoreader (Bio-Rad, USA). The
following formula was used to determine the inhibition of
cell proliferation: cell proliferation inhibited (%) = [1-(OD
of the experimental samples/OD of the control)] × 100.
The IC50 was the concentration that caused a 50% inhib-
ition of cel1 proliferation.
TUNEL assay
Hep3B cells (4 × l04 cells/ml) were seeded in growth
medium on the cover glass slides of 6-well plates for 24 h
incubation. They were then treated with the indicated
concentrations of QNT11 for 24 h. Control wells consisted
of cells incubated with medium only. After that, cells were
examined for apoptosis by terminal deoxynucleotidyl
transferase-mediated dUTP nick-end labeling (TUNEL)
assay (Promega, Madison, WI, USA), performed according
to the manufacturer’s instructions. Cells were visualized
and photographed using a fluorescent microscope (BX51,
Olympus, Japan). At least five randomly chosen areas in
every slide were used. Percent apoptosis was determined by
counting the number of apoptotic cells and dividing by the
total number of cells in the areas.
DNA agarose gel electrophoresis
Hep3B cells were treated with media containing different
concentrations of QNT11 for 24 h and were then washed
twice with PBS. The chromosomal DNA was extracted
with Apoptotic DNA Ladder Detection Kit (Beyotime,
China) according to the manufacturer’s instructions. The
DNA sample was incubated at 37°C for 30 min andelectrophoresed on a 1% agarose gel containing 1 mg/ml
ethidium bromide at 40 V/cm. Finally, the apoptotic DNA
fragments were visualized under a UV transilluminator
and photographed.
Flow cytometry analysis
Hep3B cells (1 × 106/ml) were washed twice with ice-
cold PBS and then were re-suspended gently in 500 μl of
ice-cold PBS. Thereafter, ice-cold 70% ethanol (4 ml)
was added in a dropwise manner and cells were stored
at 4°C for 12 h. After 12 h, cells were pelleted by centri-
fugation for 5 min. The supernatant was removed and
cells were re-suspended in 500 μl of PBS containing
propidium iodide (50 μg/ml) and incubated in dark con-
ditions at 37°C before analysis by FACS (Calibur, Becton
Dickinson).
Topoisomerase II-mediated supercoiled pBR322 DNA
relaxation assay
DNA topoisomeraseIIactivity was determined by the
supercoiled pBR322 DNA relaxation assay [13]. The
experiments were performed by incubating human topoi-
someraseIIα (Sigma, St Louis, MO, USA) with 1 μg super-
coiled pBR322 DNA in 5 μl relaxation buffer (200 mM
Tris–HCl, pH 7.5, 340 mM KCl, 40 mM MgCl2, 20 mM
DTT, 120 mg/L BSA, 5 mM EDTA, 4 mM ATP) under
increasing concentrations of QNT11. In this experiment,
etoposide (Sigma, St Louis, MO, USA), a known topoiso-
meraseIIpoison [14], was used as a positive control. Reac-
tions were incubated at 37°C for 30 min and terminated
by adding 20 μl 10% SDS, and 1μl protease K (1 × l04 mg/L).
Samples were subjected to electrophoresis in 1% agarose gels.
DNA was then stained with 1 mg/ml ethidium bromide and
photographed under a UV transilluminator.
Estimate of mitochondrial membrane potential loss
Hep3B cells were treated with media containing different
concentrations of QNT11 for 24 h and were then incubated
with 0.5 mg/ml of the fluorescence probe JC-1 (5,5',6,6'-
tetrachloro-l, l',3,3'- tetraethyl-benzimidazolcarbocyanine
iodide, Beyotime, China) at 37°C for 20 min. The cells were
washed twice thoroughly with buffer and incubated with 5
μg/ml. Hoechst 33258 for 10 min in the dark. After
additional washing twice, the mitochondrial membrane po-
tential (△ψm) was measured by high content screening
(HCS) image system. (Thermo Fisher Scientific, USA).
Western blot analysis
After treatments with different concentrations QNT11 for
24 h, Hep3B cells were lysed with ice-cold RIPA lysis buffer.
Protein concentrations were determined using the Bradford
method. After adjustment to a similar level of total protein
concentration, samples were separated by 12% SDS–PAGE
under reducing conditions and then transferred onto
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The membranes were blocked with 5% non-fat milk in
TBST buffer (20 mM Tris–HCl, 137 mM NaCl, and 0.1%
Tween 20, pH 8.0) for 1 h at room temperature prior to
incubation with specific antibodies to caspase-9, caspase-8,
caspase-3, Bcl-2, Bax, CDK1, CyclinB1, Cytochrome c or β-
actin (all antibodies from Santa Cruz Biotechnology) over-
night at 4°C. After washing and reaction with horseradish
peroxidase conjugated anti-mouse IgG (Beijing Zhong
Shan Golden Bridge Biological Technology CO, LTD), or
anti- rabbit IgG (Beyotime, China) secondary antibodies for
1 h, the membranes were washed with TBST buffer three
times and the proteins on the membrane were detected
using an enhanced chemiluminescene substrate (ECL,
Beyotime, China).
Cytochrome c release from mitochondria was evalu-
ated by western blot analysis of cytosolic protein
samples. Cytosolic and mitochondrial protein fractions
were prepared using the cell mitochondria isolation kit
(Beyotime, China).Figure 2 Inhibition of cell viability by QNT11 and levofloxacin treatm
cells (B), MCF-7 cells (C), HCT-8 cells (D) and BMSCs (E) were treated with
with various concentrations of Levofloxacin (F) for 12–72 h. Control cells w
(the final concentration of DMSO was below 0.1%). After treatment, cell via
calculated as a percentage of viability of the control cells. Data represent mStatistical analyses
Data are presented as the mean ± standard deviation (SD)
for the indicated number of independent experiments.
Statistical significance was calculated using the t-test for
paired samples. P < 0.05 was regarded as significant, and
P < 0.01 as highly significant.
Results
QNT11 suppressed the growth of the cancer cells in vitro
The cytotoxicity of QNT11 against cells was assessed
using MTT cell viability assay. The cells were treated
with various concentrations of QNT11 for 12,24, 48 and
72 h, resulting in a significant decrease in cell viability in
a dose- and time-dependent manner (Figure 2). Within
the four cancer cell lines used in this experiment, QNT11
was more effective against Hep3B cells. As shown in
Figure 2A, the IC50 value for 12,24, 48 and 72 h treatment
was 1.92 ± 0.19 μM (r2 = 0.9601), 2.21 ± 0.20 μM (r2 =
0.9679), 2.55 ± 0.25 μM (r2 = 0.9561) and 2.70 ± 0.22 μM
(r2 = 0.9802) respectively. For SMMC-7721 cells, the IC50ent in human cancer cells and BMSCs. Hep3B cells (A), SMMC-7721
various concentrations of QNT11 for 12–72 h. Hep3B cells were treated
ere treated with the same volume of DMSO as a vehicle control
bility was measured by MTT assay as described in Methods, and then
eans ± SD of three independent measurements.
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2.16 ± 0.28 μM (r2 = 0.9109), 2.38 ± 0.22 μM (r2 = 0.9408),
2.68 ± 0.25 μM (r2 = 0.9427) and 3.06 ± 0.19 μM (r2 =
0.9264), respectively. For MCF-7 cells, the IC50 was 2.93 ±
0.23 μM (r2 = 0.9640), 3.17 ± 0.26 μM (r2 = 0.9212), 3.11 ±
0.32 μM (r2 = 0.9490) and 3.68 ± 0.25 μM (r2 = 0.9624) for
12, 24, 48 and 72 h treatment respectively. For HCT-8
cells, the IC50 value for12, 24, 48 and 72 h treatment
obtained was 2.12 ± 0.22 μM (r2 = 0.9260), 2.79 ± 0.22 μM
(r2 = 0.9547), 2.86 ± 0.25 μM (r2 = 0.9139) and 3.46 ± 0.32
μM (r2 = 0.9174), respectively. In contrast, QNT11 had
weak cytotoxicity against BMSCs. The IC50 value for 12,
24, 48 and 72 h treatment was 8.13 ± 0.55 μM (r2 =
0.9574), 7.46 ± 0.50 μM (r2 = 0.9034), 7.90 ± 0.55 μM (r2 =
0.9414) and 12.05 ± 0.69 μM (r2 = 0.8993), respectively.
Levofloxacin had weak cytotoxicity against Hep3B
cells. The IC50 value for 12, 24, 48 and 72 h treatment
was 12.46 ± 0.41 μM (r2 = 0.6261), 10.99 ± 0.39 μM (r2 =
0.8016), 20.80 ± 0.58 μM (r2 = 0.7122) and 13.03 ± 0.46
μM (r2 = 0.8362), respectively.
QNT11 Induced apoptosis of Hep3B cells
After treatment with various concentrations of QNT11
for 24 h, TUNEL assay was used to confirm the apoptoticFigure 3 QNT11 induces apoptosis in Hep3B cells. Induction of apopto
TUNEL assay. Representative images were taken with nuclear stain DAPI, (A
overall means ± SD from three independent experiments. Statistical signific
vs control). (D) Hep3B cells treated with 0, 0.803 ( IC30 group), 2.210 (IC50 g
from 1 × 106 cells was electrophoresed through 1% agarose gels and staineeffect of QNT11. 24 h incubation with QNT11 increased
the percentage of apoptotic Hep3B cells in a concentration-
dependent manner (Figure 3A,B and C).
The integrity of DNA was assessed by agarose gel
electrophoresis. As shown in Figure 3D, 24 h incubation
of Hep3B cells with 2.210 μM and 3.616 μM QNT11
elicited a characteristic DNA “ladder” bands indicative of
apoptotic internucleosomal DNA fragmentation (about
180 ~ 200 bp).
Effects of QNT11 on the catalytic activities of eukaryotic
topoisomerase II
In this experiment, the relative effects of QNT11 on
double-stranded DNA cleavage/relegation in the pres-
ence of topoisomerase II were determined by agarose gel
electrophoresis of treated-pBR322 DNA and nontreated-
pBR322 DNA (Figure 4). QNT11 decreased the super-
coiled DNA (Form I), while increasing nicked circular
plasmid molecules (Form II) and linear molecules (Form
III) in a dose-dependent manner. The effects of QNT11
on topoisomeraseII-mediated DNA cleavage/religation
were similar to that of etoposide. This suggests that
QNT11 increased topoisomerase II-mediated DNA
breakages but inhibited DNA religation.sis in Hep3B cells treated with QNT11 for 24 h was evaluated by
) and apoptosis stain TUNEL, (B) × 200. (C) Data are expressed as
ance was determined using the Student’s t-test (* P < 0.05, ** P < 0.01
roup) and 3.616 μM (IC70 group) QNT11 respectively for 24 h. DNA
d with 0.5 μg/ml ethidium bromide.
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potential
Mitochondrial membrane potential (△ψm) was detected
with the fluorescent probe JC-1, which exists predomin-
antly in monomeric form in cells with depolarized mito-
chondria and displays green fluorescence at 490 nm. On
the other hand, JC-1 primarily forms aggregates in cells
with polarized mitochondria and shows reddish-orange
fluorescence. The emission intensity ratio of the 545 nm
and 595 nm peaks was used as a measure of the mito-
chondrial depolarization; a higher ratio indicated more
depolarization. Hep3B cells with QNT11 treatment for
24 h exhibited green JC-1 fluorescence in a dose-dependent
manner, which is consistent with a loss of △ψm (Figure 5).
After treatment with QNT11 at 0.803 μM, 2.210 μM and
3.616 μM for 24 h, △ψm of the cells decreased (9.65 ±
4.26)%, (37.34 ± 3.98)% and (45.05 ± 3.18)%, respectively, as
compared to the control (P < 0.05,T = 3.24).
Effects of QNT11 on apoptotic protein expressions in
Hep3B cells
The release of cytochrome c from mitochondria is a crit-
ical step in the apoptotic cascade that can activate down-
stream caspases. To examine whether QNT11-induced
apoptosis in Hep3B cells was associated with the release
of cytochrome c from mitochondrial, the levels of cyto-
chrome c in both the cytosolic and mitochondrial frac-
tions were analyzed. The results showed that there was a
significant increase of cytochrome c in the cytosol after
24 h treatment with QNT11 and a decrease in the mito-
chondrial fraction (Figure 6A).
To characterize the signaling pathways involved in
QNT11-induced apoptosis, the expression levels of Bcl-2,
Bax,caspase-9, caspase-8, and caspase-3 in QNT11-treated
Hep3B cells were analyzed by Western blot analysis
(Figure 6B). The anti-apoptotic protein Bcl-2 was de-
creased, while the pro-apoptotic protein Bax was increased
by QNT11 treatment. Because changes in Bax/Bcl-2 levels
have been reported in the initiation of caspase signaling, the
caspase-9 and caspase-3 activation was examined in thisFigure 4 The inhibition effects of QNT11 on DNA topoisomerase II ac
pBR322 DNA in relaxation buffer under increasing concentrations of QNT11
then stained with ethidium bromide and photographed under a UV transilstudy as well. Upon apoptotic stimulation, full length
caspase-9 and caspase-3 were cleaved into active fragments.
The results showed that the cleaved activated forms of
caspase-9 and caspase-3 increased significantly by 2.210
μM and 3.616 μM of QNT11 treatment. These results indi-
cated that QNT11 induced apoptosis in Hep3B cells
through the intrinsic mitochondrial apoptotic pathway. On
the other hand, QNT11 significantly increased the expres-
sion levels and the cleaved activated forms of caspase-8.
Caspase-8 is a prominent initiator of death receptors and is
activated by death receptor apoptosis stimuli. Therefore,
QNT11 treatment induces apoptotic death in Hep3B cells,
at least in part through death-receptor signaling pathway.
Effects of QNT11 on cell cycle distribution in Hep3B cells
As topoisomerase II inhibitors, fluoroquinolones might
increase the steady-state concentration of their covalent
DNA cleavage complexes and induce cell cycle arrest in
the G2/M phase and apoptosis. Flow cytometry and
propidium iodide was employed to demonstrate the ef-
fects of QNT11 on cell cycle distribution and possible
apoptosis induction. The sub-G1 peak and the accumula-
tion of cells in the G2/M phase accompanying reduction
in the G0/G1 phase were observed after the Hep3B cells
treatment with 3.616 μM QNT11, which suggested that
QNT11 arrested cells in G2/M phases and that this ar-
rest might result in sub-G1 formation (Figure 7).
Cyclin B1and CDK1, the master regulators in cell pro-
liferation, plays an essential role in G2/M transition of
mitosis in cell proliferation. As shown in Figure 8, the
expression of CDK1 and cyclin B1 was significantly
decreased by the treatment of QNT11 compared with
control cells. The result indicated that QNT11 induces
G2/M arrest by the inhibition of cyclin B/cdk1 complex
formation.
Discussion
Fluoroquinolone compounds have been reported to have
an inhibitory effect on cell proliferation and induce
apoptosis in carcinoma cell lines [15,16]. In this study,tivity. Human topoisomeraseIIα was incubated with supercoiled
. Samples were subjected to electrophoresis in 1% agarose gels and
luminator.
Figure 5 Effects of QNT11 on the mitochondrial membrane potential of Hep3B cells HCS analysis after JC-1 staining to detect changes
in the mitochondrial membrane potential of Hep3B cells Induced by QNT11. Cells were treated with 0, 0.803 (IC30 group), 2.210 (IC50 group)
and 3.616 μM (IC70 group) QNT11 respectively for 24 h. The mitochondrial membrane potential (△ψm) was measured by HCS image system.
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ation of human hepatocarcinoma cells in a dose- and
time-dependent manner but did not appear to disturb
the proliferation of non-cancerous BMSCs. The result
provided the evidence at QNT11 selectively suppresses
cancer cell proliferation. Thus, we propose that QNT11
could be an effective candidate for therapy against ma-
lignant tumors. Antibacterial fluoroquinolones are a
class of antibacterial agents that are commonly used to
treat human and animal infections. The treatment of
bacterial infection inhibits bacterial DNA gyrase by a
mechanism similar to that of certain antitumor drugs
against mammalian topoisomerase II [17]. Some antibac-
terial fluoroquinolones, such as ciprofloxacin, ofloxacin
and norfloxacin, also demonstrate a slight interaction
with mammalian topoisomerase II, although these anti-
bacterials are much more selective for bacterial DNA
gyrase [18]. However, a number of chemically modifed
antibacterial fuoroquinolone derivatives with enhanced
activity against mammalian topoisomerase II have been
developed. Strong inhibitory effects against eukaryotic
DNA replication were demonstrated, and their structure-
activity relationship has also been characterized [19]. These
fluoroquinolone derivatives share a similar mechanism ofFigure 6 Effects of QNT11 on apoptotic protein expressions in Hep3B
mitochondria to the cytosol were examined by western blot analysis in He
and 3.616 μM (IC70 group) of QNT11 respectively for 24 h. (B) Protein expre
examined by western blot analysis in Hep3B cells after treatment with 0, 0.
respectively for 24 h.action with several clinically relevant antitumor agents,
such as ellipticine and etoposide. They bind to the topo-
isomerase II–DNA cleavage complexes, thus converting
topoisomerase II into a physiological toxin that creates
protein-linked DNA breaks in the genome of treated cells
[20]. As shown in Figure 4, QNT11 increased topoisomer-
ase II-mediated supercoiled pBR322 DNA breaks but
inhibited topoisomerase II-mediated DNA religation. The
effects of QNT11 on the topoisomerase II-mediated DNA
cleavage/religation were similar to that of etoposide. These
findings provide evidence that QNT11 is a poisonous in-
hibitor for topoisomerase II [21]. QNT11 binds the revers-
ible complex between DNA and topoisomerase II,
preventing the dissociation of the DNA–topoisomerase II
complex and thereby inducing DNA damage. It has been
reported that the key responses of fuoroquinolone-induced
DNA damage is causing cell-cycle arrest and apoptosis of
the treated cells [22,23]. Previous studies have shown that
fuoroquinolone compounds induced G2/M cell cycle arrest
and apoptosis in a variety of carcinoma cell lines as well.
Cyclin B1 plays an essential role in G2/M transition of mi-
tosis in cell proliferation [24,25]. The results of this study
showed that the treatment with QNT11 significantly de-
creased the expression of cyclin B1/CDK1 and confirmedcells. (A) The Effects of QNT11 on the release of cytochrome c from
p3B cells after treatment with 0, 0.803 (IC30 group), 2.210 (IC50 group)
ssions levels of caspase-9, caspase-8, caspase-3, Bcl-2, and Bax were
803 (IC30 group), 2.210 (IC50 group) and 3.616 μM (IC70 group) QNT11
Figure 7 Effect of QNT11 on the cell cycle distribution in Hep3B cells. Cell cycle distribution was demonstrated by Flow cytometry analysis
in Hep3B cells after treatment with 0 (A), 0.803 (B) and 3.616 μM (C) QNT11 respectively for 24 h.
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nolone compounds on cyclin B1 down-regulation, G2/M
cell cycle arrest and induction of apoptosis.
Apoptosis may be initiated by the stimulation of death re-
ceptors located on the cell surface or through an intrinsicFigure 8 Effects of QNT11 on CDK1 and cyclin B1 protein expressions
examined by western blot analysis in Hep3B cells after treatment with 0, 0.
QNT11 respectively for 24 h.pathway involving the release of apoptotic signals from
mitochondria [26,27]. The cascading activation of caspases
and the release of cytochrome c from themitochondria play
key roles in apoptosis, and the type of intracellular apop-
totic pathways involved may be deduced from the activatedin Hep3B cells. Protein expressions levels of CDK1and cyclin B1 were
803 (IC30 group), 2.210 (IC50 group) and 3.616 μM (IC70 group) of
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mitochondria-related events during apoptosis, such as
the breakdown of the mitochondrial membrane, the
expression of Bax and Bcl-2, and the activation of
caspase-9. Members of the Bcl-2 protein family play an
important role in apoptosis by regulating the release of
cytochrome c from the mitochondria to the cytosol
[28]. It has been shown that anti-apoptotic proteins,
such as Bcl-2 and Bcl-XL, inhibit cytochrome c release
whereas pro-apoptotic members, such as Bax, promote
cytochrome c release, leading to the initiation of
apoptosis. Here, we observe that QNT11 mediated an
up-regulation of Bax and down-regulation of Bcl-2 to
induce apoptosis, possibly through increased caspase
activity and by preventing the formation of anti-
apoptotic bodies. Therefore, it is possible that QNT11
induced the opening of the mitochondrial permeability
transition pore through the up-regulation of Bax,
resulting in the release of cytochrome c [29,30]. In fact,
we observed a QNT11-induced decrease of the mitochon-
drial membrane potential in Hep3B cells, followed by in-
creased cytochrome c release from the mitochondria into
the cytosol. In the mitochondrial apoptotic pathway, the
release of cytochrome c is a critical event because cyto-
chrome c forms a complex with procaspase-9 in the cyto-
plasm (resulting in the activation of procaspase-9), which
will eventually lead to the activation of caspases-3 and the
induction of apoptosis [31]. Because caspase-8, when
activated by the death receptor, is able to cleave the
proapoptotic Bcl-2 family member and then trigger a dis-
tinct apoptotic pathway involving mitochondria in some
fuoroquinolone compound-treated cell types, it is possible
that the activation of caspase-9 in QNT11-treated Hep3B
cells may be due to the activation of the death receptor-
caspase-8 pathway [32,33]. Our results showed that the
cleavage of caspase-8 was increased significantly in
QNT11-treated cells. Therefore, it is likely that the acti-
vation of caspase-9 is triggered mainly by the caspase-8
pathway. However, this needs further evaluation by
using caspase inhibitors [34].Conclusions
Taken together, we conclude that QNT11 selectively
suppressed cancerous cells proliferation through the
mechanism of eukaryotic topoisomerase II poisoning.
The growth inhibition was in large part mediated via
apoptosis-associated mitochondrial dysfunction and re-
gulation of Bcl-2 signaling pathways. The subsequent
activation of caspase cascades plays a critical role in
QNT11-induced apoptosis in human hepatocarcinoma
Hep3B cells. QNT11 may, therefore, have a potential
use as a novel chemotherapeutic agent in the treatment
of liver cancer, as well as other solid cancers.Abbreviations
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